Biocatalytic nitro-reductions in scalable continuous flow reactors: paracetamol case study

**HydRegen vision：** HydRegen技术提供了更清洁，更安全，更快、更便宜的化学品制造。对生物学和化学的深入了解使HydRegen团队能够从生物学中选择最好的成分，并利用它们开发强大的生物技术，解决化学品行业的真实的问题。我们希望我们的技术在英国化学品行业中发挥作用，以实现雄心勃勃的净零排放目标（到2050年），并增加采用工业生物催化和连续流工艺等使能技术。目前，我们正在应对制药和特种化学品制造方面的挑战。（例如香精香料），并探索我们的技术在大规模、低价值化学品生产中的潜力。** AMT：** 获得专利的主动混合技术为各种工艺开辟了连续生产的道路，减轻了与固体颗粒存在相关的挑战，例如在非均相催化加氢反应中。Coflore连续流反应器系列提供了一种可扩展的制造解决方案，年产量从克到千吨不等，降低了从研发到中试再到商业规模的技术转移风险。根据普华永道2021年的一份报告，与现有的批量生产方法相比，连续制造可以将能源效率提高50%，并减少33%的浪费。能源危机和新冠肺炎等全球压力，项目成果：* 展示两种通用活性药物成分和包装的无风险生物制造路线，以获得英国和全球化学品生产商的许可。*在提供生物制造能力方面提高竞争力和商业声誉，到2050年提供颠覆性的可持续生物制造战略。评估生物基路线的“硝化”化学和因此生物级联的硝化还原特种化学品制造。

**HydRegen vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture.Deep understanding of biology and chemistry allow the HydRegen team to select the best components from biology and use them to develop robust biotechnologies that solve real problems in the chemicals sectors.We expect our technologies to play a part in the UK chemicals sector meeting ambitious Net Zero emissions targets (by 2050) and increasing adoption of enabling technologies such as Industrial Biocatalysis and continuous flow process.Currently we are addressing challenges in the manufacture of pharmaceuticals and speciality chemicals (e.g. flavours and fragrances) and exploring the potential of our technologies for larger-scale, lower-value chemical production.**AMT:** The patented active mixing technology opens up continuous manufacturing for a wide range of processes, mitigating challenges associated with the presence of solid particles, such as in heterogenous catalytic hydrogenation reactions. The range of Coflore continuous flow reactors offer a scalable manufacturing solution from grams to kilotonnes production per annum, de-risking tech transfer from R&D to pilot to commercial scale.According to a 2021 report by PwC, continuous manufacturing can increase energy efficiency up to 50% and reduce waste by 33% compared to existing batch methods of production.Global pressures such as the energy crisis and covid, have led EU and USA based companies to look to "re-shore" production away from India and China to strengthen supply chains.Project outcomes:* Showcase de-risked, bio-manufacturing route for two generic active pharmaceutical ingredients and package for licensing to UK and global chemical producers.* Improved competitivity and commercial-reputation in delivering bio-manufacturing capabilities providing a disruptive sustainable bio-manufacturing strategy by 2050\.* Evaluation of bio-based route to 'nitration' chemistry and consequently bio-cascades for nitration-reduction in specialty chemical manufacturing.